Hypoxia-induced RBM47 regulates the alternative splicing of FN1 in glioblastoma via intracellular and exosome-mediated mechanisms to promote invasiveness

Inside the human body, cancer cells do not exist in isolation; they live within a bustling, shifting neighborhood known as the tumor microenvironment. This neighborhood is crowded with blood vessels, immune cells, and the structural scaffolding that holds tissues together. In aggressive brain tumors called glioblastomas, this environment often becomes starved of oxygen, a condition scientists call hypoxia. While a lack of oxygen might seem like a death sentence for any cell, cancer cells are notorious for adapting to these harsh conditions. They do not just survive; they use the stress of low oxygen to become more dangerous, spreading into healthy brain tissue and resisting treatment. To understand how this happens, researchers look at two specific tools cancer cells use to change their behavior: the way they edit their own genetic instructions and the tiny packages they send to their neighbors to share those instructions.

Genetic instructions are stored in DNA, but to build a working protein, the cell must first copy a segment of DNA into a molecule called RNA. This RNA copy often contains extra sections that must be cut out, a process known as splicing. By choosing which sections to keep and which to discard, a single gene can produce different versions of a protein, each with a slightly different job. This flexibility allows cells to adapt quickly. Meanwhile, cells also communicate by releasing exosomes, which are microscopic bubbles that float through the fluid surrounding the cells. These bubbles carry proteins and genetic material from one cell to another, effectively allowing a cell to change the behavior of its neighbors without ever touching them. When these two mechanisms—editing genetic instructions and sharing them via bubbles—combine under the stress of low oxygen, they create a powerful engine for tumor growth.

A team of researchers at the Indian Institute of Science Education and Research Bhopal and the All India Institute of Medical Sciences has uncovered a specific chain of events that links these processes in glioblastoma. They discovered that when brain tumor cells are starved of oxygen, they activate a protein called RBM47. This protein acts as a master editor for the cell's genetic instructions. Under normal conditions, RBM47 is present at low levels, but when oxygen drops, a master regulator protein called HIF1-alpha turns on the gene that makes RBM47, causing its levels to rise sharply. Once abundant, RBM47 goes to work on a specific gene called FN1, which produces a structural protein called fibronectin. Fibronectin helps cells stick to their surroundings and move around. The researchers found that RBM47 forces the cell to keep a specific section of the FN1 gene that is usually discarded in healthy adult tissues. This results in a version of the protein that is sticky and aggressive, helping the cancer cells crawl through the brain and invade new territory.

The discovery took a surprising turn when the researchers looked at how this aggressive behavior spreads beyond the cells that are directly suffering from low oxygen. They found that the hypoxic cells do not keep the RBM47 protein to themselves. Instead, they package it into exosomes and release them into the surrounding fluid. When these exosomes are taken up by neighboring cells that are sitting in normal, oxygen-rich conditions, they deliver a dose of RBM47. This transfer tricks the healthy neighbors into thinking they are also under stress. The recipient cells begin to produce the same aggressive version of the fibronectin protein, even though they have plenty of oxygen. This means that a small, oxygen-starved core of the tumor can effectively turn the entire tumor mass into an invasive force, spreading the dangerous behavior to cells that would otherwise remain relatively calm.

To prove that this process was real and to understand exactly how it worked, the scientists performed a series of precise experiments. They grew brain tumor cells in the lab and exposed some to low oxygen while keeping others in normal air. They confirmed that the low-oxygen cells produced much more RBM47 and that this increase was driven directly by the HIF1-alpha protein binding to the RBM47 gene. They then isolated the exosomes from these cells and treated normal, oxygen-rich cells with them. The normal cells absorbed the exosomes and immediately began producing high levels of RBM47, confirming that the protein was being physically transferred from one cell to another. To see if this transfer actually changed the cells' behavior, they placed the treated cells in a special chamber that measured how easily they could push through a barrier. The cells that had received the exosomes from the low-oxygen group pushed through the barrier much more easily than the control cells, proving that the exosomes had successfully made them more invasive.

The team then zoomed in on the genetic editing process to see exactly how RBM47 changed the fibronectin protein. They identified a specific sequence of letters in the RNA instructions for fibronectin that RBM47 likes to grab onto. When RBM47 binds to this spot, it prevents the cell from cutting out a specific section of the gene, forcing the cell to include it in the final protein. This inclusion creates the aggressive version of fibronectin. To test if this was the only way the protein worked, the researchers used a tool that acts like a pair of molecular scissors to block this specific binding spot. When they blocked the spot, the cells stopped making the aggressive version of fibronectin, and their ability to invade the barrier dropped significantly. This confirmed that RBM47's ability to edit the gene was the direct cause of the increased invasion.

The researchers also looked at real patient data to see if this mechanism mattered in actual human disease. They analyzed genetic information from hundreds of glioblastoma patients and found that those with high levels of RBM47 had a much poorer outlook than those with low levels. Furthermore, when they examined blood samples from patients, they found that the exosomes circulating in the blood of patients with glioblastoma were rich in RBM47, whereas healthy individuals had very little. This suggests that the mechanism they observed in the lab is active in people with the disease and that the aggressive behavior of the tumor is being broadcast throughout the body via these tiny bubbles.

This study reveals a sophisticated two-part strategy that glioblastoma uses to survive and spread. First, the tumor cells use low oxygen as a signal to turn on a genetic editor that makes them more aggressive. Second, they package this editor into exosomes and send it to their neighbors, turning the entire tumor into a unified, invasive force. By showing that a single protein can be both a genetic switch inside a cell and a message sent between cells, the researchers have identified a new way that cancer coordinates its attack. The findings suggest that if doctors could block the production of this protein or stop the exosomes from delivering it, they might be able to slow down the spread of the tumor. While this research does not yet offer a cure, it provides a clear map of a critical pathway that drives one of the most difficult cancers to treat, pointing toward new targets for future therapies.